<DOC>
	<DOCNO>NCT00411697</DOCNO>
	<brief_summary>The purpose study determine 5 year age persistence immunity hepatitis B confer infant vaccination Infanrix hexa™ . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Persistence Hepatitis B Antibody Levels &amp; Immune Response Hepatitis B Vaccine Challenge</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Hepatitis B Antibodies</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol A male female 4 5 year age time enrolment . With documented evidence previous vaccination four consecutive dos Infanrix hexa™ Germany . Written inform consent obtain parent guardian subject time enrolment . Healthy subject establish medical history clinical examination enter study . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous hepatitis B booster vaccination since administration fourth dose Infanrix hexa™ booster second year life . History intercurrent hepatitis B disease . Hepatitis B vaccination birth . Planned administration/administration vaccine foreseen study protocol period start 30 day booster vaccination end 30 day . Administration immunoglobulins and/or blood product within three month precede booster vaccination plan administration study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior HBV vaccine challenge .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>